New trial aims to snuff out hidden leukemia before it returns
NCT ID NCT06664879
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests whether a combination of two drugs, MBG-453 and azacitidine, can eliminate leftover cancer cells in people with acute myeloid leukemia (AML). The goal is to prevent relapse by treating the disease when it is still at a very low level. Only 3 participants are enrolled so far, making this a very small and early study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MBG-453 and azacitidine
What this could lead to
If successful, this could point toward a way to prevent AML relapse by treating early signs of remaining cancer.
What could go wrong
This is a very early trial with only 3 participants, so results may not apply broadly. The drugs may cause side effects or fail to stop the cancer from returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States